Transthyretin amyloidosis cardiomyopathy in patients with HFpEF in Russia

Trial Identifier: D8450R00006
Sponsor: AstraZeneca
Start Date: December 2023
Primary Completion Date: June 2024
Study Completion Date: June 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia Akhtubinsk, Russia
Russia Astrakhan, Russia
Russia Barnaul, Russia
Russia Beslan, Russia
Russia Chelyabinsk, Russia
Russia Ekaterinburg, Russia
Russia Izhevsk, Russia
Russia Kaluga, Russia
Russia Kazan, Russia
Russia Khabarovsk, Russia
Russia Kirov, Russia
Russia Krasnodar, Russia
Russia Nizhny Novgorod, Russia
Russia Omsk, Russia
Russia Rostov-on-Don, Russia
Russia Smolensk, Russia
Russia Ufa, Russia
Russia Vladimir, Russia
Russia Vladivostok, Russia
Russia Volgograd, Russia
Russia Yaroslavl, Russia